一种具有抑制人结直肠癌细胞增殖作用的重组蛋白的制备与应用
By using recombinant protein Amuc_1434, the problems of drug resistance and large side effects in existing colorectal cancer treatments have been solved, achieving safe and efficient colorectal cancer treatment.
CN118063568BActive Publication Date: 2026-07-17JILIN UNIVERSITY
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- JILIN UNIVERSITY
- Filing Date
- 2024-03-03
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing colorectal cancer treatments such as oxaliplatin have problems such as secondary drug resistance and significant side effects, necessitating the search for safe and effective new treatment strategies.
Method used
The recombinant protein Amuc_1434, derived from the intestinal bacterium Akkermansia muciniphila, was used alone or in combination with oxaliplatin to inhibit the proliferation of colorectal cancer cells, induce apoptosis, and enhance drug sensitivity.
Benefits of technology
Recombinant protein Amuc_1434 significantly inhibits the proliferation of colorectal cancer cells, induces apoptosis, enhances the therapeutic effect of oxaliplatin, reduces side effects, and enhances the drug sensitivity of drug-resistant cells.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN118063568B_ABST
Abstract
本发明涉及一种具有抑制人结直肠癌细胞增殖作用的重组蛋白的制备与应用，该重组蛋白名称为Amuc_1434，具有抑制人结直肠癌细胞(SW480和HCT‑116)增殖作用。重组蛋白Amuc_1434来源于肠道菌Akkermansia muciniphila ATCC BAA‑835，其氨基酸序列如SEQ ID NO：1所示，基因序列如SEQ ID NO：2所示。经外源表达的重组蛋白Amuc_1434具有抑制结直肠癌细胞增殖及诱导肠癌细胞凋亡的功能，且不会影响正常细胞的活性。除此之外，重组蛋白Amuc_1434与奥沙利铂联合使用可有效提升奥沙利铂对结直肠癌细胞的增殖抑制的效果，增强结直肠癌耐药细胞对奥沙利铂的药物敏感性。Amuc_1434在制备用于治疗或辅助治疗人类结直肠癌的重组蛋白药物上具有潜在的应用价值以及广阔的应用前景。
Need to check novelty before this filing date? Find Prior Art